METHYCLOTHIAZIDE AND DESERPIDINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METHYCLOTHIAZIDE AND DESERPIDINE (METHYCLOTHIAZIDE AND DESERPIDINE).
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
| Metabolism | Methyclothiazide: not extensively metabolized; Deserpidine: extensively metabolized in the liver via CYP450 enzymes. |
| Excretion | Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%). |
| Half-life | Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing. |
| Protein binding | Methyclothiazide: 90-95% bound to albumin; Deserpidine: approximately 95% bound to plasma proteins (albumin and alpha-1 acid glycoprotein). |
| Volume of Distribution | Methyclothiazide: 0.3-0.6 L/kg, consistent with distribution in extracellular fluid; Deserpidine: 1-2 L/kg, indicating extensive tissue binding and distribution. |
| Bioavailability | Methyclothiazide: oral bioavailability 60-70% due to first-pass metabolism; Deserpidine: oral bioavailability 40-50% due to extensive first-pass hepatic metabolism. |
| Onset of Action | Methyclothiazide: diuresis within 2 hours after oral administration; Deserpidine: oral dose, antihypertensive effect occurs over several days to weeks. |
| Duration of Action | Methyclothiazide: diuretic effect lasts 12-24 hours; Deserpidine: antihypertensive effect persists for 1-2 weeks after discontinuation due to slow elimination. |
| Molecular Weight | 478.3 |
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in anuria. For GFR 30-60 mL/min: use with caution, monitor electrolytes. For GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment needed. Child-Pugh B: use with caution due to potential for hepatic encephalopathy. Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for use in children; safety and efficacy not established. |
| Geriatric use | Start with half the standard dose (0.5 tablet) once daily due to increased sensitivity to hypotension, electrolyte disturbances, and CNS effects. Titrate slowly. |
| 1st trimester | Contraindicated: risk of teratogenicity (neural tube defects, cardiovascular malformations) due to folic acid antagonism by methyclothiazide; deserpidine may cause fetal bradycardia. |
| 2nd trimester | Contraindicated: may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances; deserpidine may deplete fetal catecholamines. |
| 3rd trimester | Contraindicated: risk of neonatal hypoglycemia, hypokalemia, and respiratory depression; deserpidine may cause neonatal bradycardia and hypotension. |
Clinical note
Comprehensive clinical and safety monograph for METHYCLOTHIAZIDE AND DESERPIDINE (METHYCLOTHIAZIDE AND DESERPIDINE).
| Placental transfer | Both components cross the placenta; methyclothiazide achieves similar concentrations in fetal and maternal blood; deserpidine has documented placental transfer. |
| Breastfeeding | Methyclothiazide may suppress lactation; deserpidine is excreted in breast milk and may cause infant bradycardia, respiratory depression, and gastrointestinal effects. Recommend avoid breastfeeding or discontinue drug. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to thiazides or reserpine derivativesHistory of depression or suicidal ideationActive peptic ulcerUlcerative colitisSevere renal impairment (CrCl <30 mL/min)AnuriaHepatic coma or pre-comaElectrolyte imbalance (uncorrected hypokalemia, hyponatremia)
| Precautions | Possible exacerbation or activation of systemic lupus erythematosus, Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia), Orthostatic hypotension, Depression (due to deserpidine component), Potential for mental depression, especially in patients with history of depression |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, leafy greens) unless directed, due to risk of hyperkalemia with deserpidine. Limit alcohol consumption. Maintain adequate fluid intake unless fluid restriction is advised. |
Loading safety data…
| Lactation Rating | Avoid |
| Teratogenic Risk | Methyclothiazide: Thiazide diuretics cross the placenta and may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use in pregnancy, especially during the second and third trimesters, is associated with reduced placental perfusion and potential fetal harm; generally avoided for pregnancy-induced hypertension due to maternal hypovolemia risk. Deserpidine: Reserpine alkaloids cross the placenta and may increase respiratory secretions, nasal congestion, cyanosis, and hypothermia in neonates; also associated with increased risk of congenital malformations if used in first trimester. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes (especially potassium and sodium), renal function, and uric acid levels. Observe neonate for jaundice, thrombocytopenia, electrolyte disturbances, and respiratory depression. Consider placental perfusion assessment with Doppler if used in pregnancy. |
| Fertility Effects | Thiazide diuretics may rarely cause erectile dysfunction; deserpidine may impair fertility via neuroendocrine effects. Limited data; no significant female fertility issues reported. |
| Clinical Pearls | METHYCLOTHIAZIDE AND DESERPIDINE combines a thiazide diuretic with a rauwolfia alkaloid. Monitor serum potassium and uric acid regularly due to diuretic-induced hypokalemia and hyperuricemia. Deserpidine may cause bradycardia and orthostatic hypotension; assess heart rate and blood pressure when initiating or changing dose. Avoid use in patients with history of depression, peptic ulcer disease, or pheochromocytoma. Discontinue at least 2 weeks before elective surgery to reduce risk of hypotension. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily in the morning to prevent nighttime urination. · Stand up slowly from sitting or lying down to avoid dizziness from low blood pressure. · Avoid alcohol, as it may worsen dizziness and drowsiness. · Report any signs of electrolyte imbalance such as muscle cramps, weakness, or irregular heartbeat. · Do not stop suddenly; tapering may be needed to avoid rebound hypertension. |